查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1766136

全球體外大腸直腸癌篩檢市場：2032 年預測 - 按測試類型、影像類型、交付方式、應用、最終用戶和地區進行分析

In-vitro Colorectal Cancer Screening Tests Market Forecasts to 2032 - Global Analysis By Test Type, Imaging Type, Mode of Offering, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球體外大腸癌篩檢市場預計在 2025 年將達到 12.9 億美元，預計到 2032 年將達到 21.7 億美元，預測期內的複合年成長率為 7.7%。

體外大腸直腸癌篩檢檢測是一種非侵入性診斷方法，可透過分析糞便或血液等體外生物樣本來檢測大腸直腸癌的早期徵兆。這些檢測可以識別潛血、DNA突變以及與惡性腫瘤和癌前息肉相關的蛋白質指標等生物標記。常用方法包括大便潛血試驗(FOBT)、糞便免疫化學檢測 (FIT) 和基於 DNA 的檢測。這些檢測旨在用於常規篩檢，有助於早期發現癌症，改善治療效果，並在症狀出現之前發現癌症，從而降低死亡率。

根據《柳葉刀腫瘤學》的報導，多目標糞便 DNA 測試（例如 Cologuard）在檢測結腸直腸癌方面的靈敏度超過 90%，在檢測晚期腺瘤方面的靈敏度約為 42%。

大腸直腸癌發生率和盛行率上升

對於尋求改善患者治療效果並降低治療成本的醫療保健提供者而言，早期檢測正成為首要任務。隨著公共衛生計畫持續強調對45歲及以上人口進行定期篩檢，預計檢測量將大幅成長。此外，癌症協會和政府機構的宣傳活動也推動了對非侵入性檢測的需求。人們日益認知到篩檢是一種預防策略，而非被動應對，這進一步佐證了這一趨勢。

常規檢測的敏感性和特異性降低

傳統的篩檢方法，例如癒創木脂檢測和過時的糞便檢測，通常敏感性和特異性有限，導致假陽性和漏診。這些缺陷降低了臨床醫生和患者對檢測的信心，並阻礙了採用大腸鏡檢查等更明確的診斷方法。此外，由於生物標記可見度較差，檢測延遲的風險可能導致無症狀患者的病情進展。

向服務不足和資源匱乏的環境擴張

農村和資源匱乏的地區通常缺乏先進的診斷基礎設施，這構成了一個尚未開發的龐大市場。攜帶式、無需專業知識的自助式試劑套件可以填補這一空白，尤其是透過政府支持的社區健康計畫進行分發。隨著官民合作關係的擴展，相關人員越來越注重透過根據不同的社會經濟背景客製化篩檢解決方案來改善醫療保健公平性。

對結果的誤解和過度診斷/診斷不足

不準確的結果可能導致過度診斷，使患者面臨侵入性干預，或診斷不足，從而延誤治療並降低療效。不同族群檢測結果的差異增加了臨床的複雜性，需要謹慎應用並由專家監督。此外，醫療系統中指南的不標準化也導致結果解釋和追蹤通訊協定的混亂。這些因素引發了人們對責任問題的擔憂，並凸顯了對臨床醫生進行培訓和製定更完善的檢驗通訊協定的必要性。

COVID-19的影響：

COVID-19 疫情擾亂了全球癌症篩檢服務，並延遲了大腸直腸疾病的早期診斷。封鎖和醫院就診限制減少了常規篩檢，導致大量未確診病例積壓。另一方面，疫情凸顯了居家和遠距離診斷的價值，促使人們對自助採集套件以及與遠端醫療結合的檢測方法重新燃起興趣。此類行為變化可能會對篩檢策略產生持久影響，並可能加速體外診斷解決方案的發展。

預計大便潛血試驗（FOBT）部分在預測期內將佔據最大的佔有率。

大便潛血試驗(FOBT) 因其成本效益高、普及性強且非侵入性，預計將在預測期內佔據最大的市場佔有率。 FOBT 在許多國家癌症預防計畫中被用作第一線篩檢工具，易於分發和管理。其便利性和極低的基礎設施要求使其成為在已開發市場和新興市場大規模部署的理想選擇。

MarCarePlex 部門預計在預測期內實現最高複合年成長率

在預測期內，MarCarePlex 細分市場預計將呈現最高成長率，這得益於其多重生物標記方法和高診斷準確性。這些先進的檢測方法能夠同時檢測多種癌症特異性標記物，從而提供更全面的風險評估。它們能夠有效識別早期惡性腫瘤，因此對於尋求精準且可擴展的檢測解決方案的臨床實驗室而言極具吸引力。

比最大的地區

由於完善的篩檢指南和廣泛的醫療保險計劃，北美預計將在預測期內佔據最大的市場佔有率。美國疾病管制與預防中心 (CDC) 和美國癌症協會 (ACS) 等機構進行的廣泛宣傳宣傳活動和積極的篩檢計畫正在提高各年齡層的參與率。雄厚的癌症預防研究資金和早期技術應用進一步提升了該地區的市場前景。

複合年成長率最高的地區：

在預測期內，由於公共衛生計畫的不斷增加以及對預防性診斷的日益重視，預計歐洲地區將呈現最高的複合年成長率。德國、英國和法國等國家正在擴大其國家癌症篩檢計劃，將高風險族群納入其中。技術創新，尤其是生物標記發現和人工智慧主導的分析，正在該地區的醫療科技生態系統中日益受到關注。

免費客製化服務

本報告的所有訂閱者均可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他公司（最多 3 家）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 市場機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

5. 全球體外大腸直腸癌篩檢測試市場（依測試類型）

  • 大便潛血試驗（FOBT）
    • 癒創木脂糞便潛血試驗（gFOBT）
    • 糞便免疫化學檢查（FIT 或 iFOBT）
  • 糞便DNA檢測（sDNA）
    • 多目標糞便DNA檢測
    • 甲基化基因檢測
    • 面板 DNA 檢測
  • 生物標記檢測（血液檢測）
    • 腫瘤M2-PK糞便檢驗
    • 轉鐵蛋白測定
    • 血漿甲基化 SEPT9 DNA 檢測
    • 液態生物檢體
  • 其他類型的測試

6. 全球體外大腸直腸癌篩檢檢測市場（依影像類型）

  • 大腸鏡檢查
  • 直腸鏡檢查
  • 電腦斷層掃描
  • 超音波
  • PET掃描
  • MRI

7. 全球體外大腸直腸癌篩檢測試市場（以交付方式）

  • 醫師主導的篩檢
  • 直接面對消費者（DTC）的家用檢測

8. 全球體外大腸直腸癌篩檢測試市場（依應用）

  • MarCarePlex
  • Cologic
  • Colox
  • miRDIGN
  • PanCDx
  • MeSorce CRC

9. 全球體外大腸直腸癌篩檢測試市場（依最終用戶分類）

  • 醫院
  • 診所
  • 診斷實驗室
  • 門診手術中心
  • 其他最終用戶

第10章 全球體外大腸直腸癌篩檢測試市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併與收購（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Sysmex Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Quest Diagnostics Incorporated
  • OncoCyte Corporation
  • Merck KGaA
  • Kyowa Kirin Co., Ltd.
  • Invitae Corporation
  • Immunostics Inc.
  • Illumina, Inc.
  • Hologic, Inc.
  • Genomic Health, Inc.
  • F. Hoffmann-La Roche AG
  • Exact Sciences Corporation
  • Epigenomics AG
  • Eiken Chemical Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter Inc.
  • Abbott Laboratories
Product Code: SMRC29992

According to Stratistics MRC, the Global In-vitro Colorectal Cancer Screening Tests Market is accounted for $1.29 billion in 2025 and is expected to reach $2.17 billion by 2032 growing at a CAGR of 7.7% during the forecast period. In-vitro colorectal cancer screening tests are non-invasive diagnostic procedures that analyze biological samples typically stool or blood outside the body to detect early signs of colorectal cancer. These tests identify biomarkers such as occult blood, DNA mutations, or protein indicators associated with malignancies or precancerous polyps. Common methods include fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and DNA-based assays. Designed for routine screening, they support early detection, improve treatment outcomes, and reduce mortality by identifying cancer before symptoms appear

According to article in The Lancet Oncology, multitarget stool DNA tests (such as Cologuard) showed a sensitivity of over 90% for detecting colorectal cancer and around 42% for advanced adenomas.

Market Dynamics:

Driver:

Rising incidence and prevalence of colorectal cancer

Early detection is becoming a top priority for healthcare providers aiming to improve patient outcomes and reduce treatment costs. As public health programs continue emphasizing routine screening for individuals aged 45 and above, test volumes are expected to rise substantially. Moreover, awareness initiatives by cancer associations and governmental bodies are bolstering demand for non-invasive testing. This trend is further supported by the growing recognition of screening as a preventive strategy rather than a reactive measure.

Restraint:

Lower sensitivity and specificity of traditional tests

Conventional screening options, such as guaiac-based tests or outdated fecal assays, often suffer from limited sensitivity and specificity, resulting in false positives or missed diagnoses. These shortcomings can erode clinician and patient confidence in the tests, discouraging adoption in favor of more definitive diagnostics like colonoscopy. Additionally, the risk of under-detection due to low biomarker visibility may lead to disease progression in asymptomatic patients.

Opportunity:

Expansion into underserved and low-resource settings

Populations in rural or low-resource settings often lack access to advanced diagnostic infrastructure, creating a large untapped market. Portable, self-administered kits that require minimal expertise can bridge this gap, especially when distributed through government-backed community health programs. As public-private partnerships expand, stakeholders are increasingly focused on improving healthcare equity by tailoring screening solutions to diverse socioeconomic contexts.

Threat:

Misinterpretation of results and over-diagnosis/under-diagnosis

Inaccurate results may lead to over-diagnosis, subjecting patients to invasive interventions, or under-diagnosis, delaying treatment and worsening prognosis. Variability in test performance across populations adds to clinical complexity, requiring cautious application and expert oversight. Additionally, non-standardized guidelines across healthcare systems contribute to confusion in result interpretation and follow-up protocols. These factors heighten liability concerns and emphasize the need for clinician training and better validation protocols.

Covid-19 Impact:

The COVID-19 pandemic introduced disruptions to cancer screening services worldwide, delaying early diagnosis of colorectal conditions. Lockdowns and restricted hospital access led to a decline in routine check-ups, causing a backlog of undiagnosed cases. On the other hand, the pandemic highlighted the value of home-based and remote diagnostics, prompting renewed interest in self-collection kits and telehealth-integrated testing. This shift in behavior is likely to have lasting effects on screening strategies and could serve as a growth accelerator for in-vitro solutions.

The fecal occult blood test (FOBT) segment is expected to be the largest during the forecast period

The fecal occult blood test (FOBT) segment is expected to account for the largest market share during the forecast period due to its cost-effectiveness, wide availability, and non-invasive nature. Used as a frontline screening tool in numerous national cancer prevention programs, FOBTs are easily distributed and administered. Their convenience and minimal infrastructure requirements make them ideal for large-scale deployments across both developed and emerging markets.

The marcareplex segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the marcareplex segment is predicted to witness the highest growth rate driven by its multiplex biomarker approach and high diagnostic precision. These advanced assays can detect multiple cancer-specific markers simultaneously, providing a more comprehensive risk assessment. Their efficiency in identifying early-stage malignancies makes them attractive for clinical labs seeking accurate yet scalable testing solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to well-established screening guidelines and expansive health coverage systems. Widespread awareness campaigns and proactive screening initiatives by agencies like the CDC and ACS have boosted participation rates across demographics. Strong funding for cancer prevention research and early technology adoption further enhance the regional market outlook.

Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR owing to increased public health initiatives and growing emphasis on preventive diagnostics. Countries such as Germany, the U.K., and France are expanding national cancer screening programs to include high-risk populations. Technological innovation, particularly in biomarker discovery and AI-driven analytics, is gaining traction in the region's med-tech ecosystem.

Key players in the market

Some of the key players in In-vitro Colorectal Cancer Screening Tests Market include Sysmex Corporation, Siemens Healthcare GmbH, Randox Laboratories Ltd., Quest Diagnostics Incorporated, OncoCyte Corporation, Merck KGaA, Kyowa Kirin Co., Ltd., Invitae Corporation, Immunostics Inc., Illumina, Inc., Hologic, Inc., Genomic Health, Inc., F. Hoffmann-La Roche AG, Exact Sciences Corporation, Epigenomics AG, Eiken Chemical Co., Ltd., Bio-Rad Laboratories, Inc., Beckman Coulter Inc. and Abbott Laboratories.

Key Developments:

In June 2025, Illumina agreed to buy proteomics company SomaLogic for $350 million plus milestones, bolstering its multiomics capabilities. The deal enhances its strategy across genomics, proteomics, and personalized medicine

In May 2025, Siemens Healthineers launched the first U.S. Mobile Stroke Unit equipped with a Somatom On.site CT scanner to deliver advanced stroke diagnostics at UCLA Health. This rapid-response ambulance aims to reduce treatment delays and improve outcomes.

Test Types Covered:

  • Fecal Occult Blood Test (FOBT)
  • Stool DNA Test (sDNA)
  • Biomarker Tests (Blood-based Tests)
  • Other Test Types

Imaging Types Covered:

  • Colonoscopy
  • Proctoscopy
  • CT Scan
  • Ultrasound
  • PET Scan
  • MRI

Mode of Offerings Covered:

  • Physician-Led Screening
  • Direct-to-Consumer (DTC) Home Testing

Applications Covered:

  • MarCarePlex
  • Cologic
  • Colox
  • miRDIGN
  • PanCDx
  • MeSorce CRC

End Users Covered:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type

  • 5.1 Introduction
  • 5.2 Fecal Occult Blood Test (FOBT)
    • 5.2.1 Guaiac FOBT (gFOBT)
    • 5.2.2 Fecal Immunochemical Test (FIT or iFOBT)
  • 5.3 Stool DNA Test (sDNA)
    • 5.3.1 Multitarget Stool DNA Testing
    • 5.3.2 Methylated Gene Testing
    • 5.3.3 Panel DNA Tests
  • 5.4 Biomarker Tests (Blood-based Tests)
    • 5.4.1 Tumor M2-PK Stool Test
    • 5.4.2 Transferrin Assays
    • 5.4.3 Plasma Methylated SEPT9 DNA Assay
    • 5.4.4 Liquid Biopsy
  • 5.5 Other Test Types

6 Global In-vitro Colorectal Cancer Screening Tests Market, By Imaging Type

  • 6.1 Introduction
  • 6.2 Colonoscopy
  • 6.3 Proctoscopy
  • 6.4 CT Scan
  • 6.5 Ultrasound
  • 6.6 PET Scan
  • 6.7 MRI

7 Global In-vitro Colorectal Cancer Screening Tests Market, By Mode of Offering

  • 7.1 Introduction
  • 7.2 Physician-Led Screening
  • 7.3 Direct-to-Consumer (DTC) Home Testing

8 Global In-vitro Colorectal Cancer Screening Tests Market, By Application

  • 8.1 Introduction
  • 8.2 MarCarePlex
  • 8.3 Cologic
  • 8.4 Colox
  • 8.5 miRDIGN
  • 8.6 PanCDx
  • 8.7 MeSorce CRC

9 Global In-vitro Colorectal Cancer Screening Tests Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Diagnostic Laboratories
  • 9.5 Ambulatory Surgical Centers
  • 9.6 Other End Users

10 Global In-vitro Colorectal Cancer Screening Tests Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Sysmex Corporation
  • 12.2 Siemens Healthcare GmbH
  • 12.3 Randox Laboratories Ltd.
  • 12.4 Quest Diagnostics Incorporated
  • 12.5 OncoCyte Corporation
  • 12.6 Merck KGaA
  • 12.7 Kyowa Kirin Co., Ltd.
  • 12.8 Invitae Corporation
  • 12.9 Immunostics Inc.
  • 12.10 Illumina, Inc.
  • 12.11 Hologic, Inc.
  • 12.12 Genomic Health, Inc.
  • 12.13 F. Hoffmann-La Roche AG
  • 12.14 Exact Sciences Corporation
  • 12.15 Epigenomics AG
  • 12.16 Eiken Chemical Co., Ltd.
  • 12.17 Bio-Rad Laboratories, Inc.
  • 12.18 Beckman Coulter Inc.
  • 12.19 Abbott Laboratories

List of Tables

  • Table 1 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 3 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Fecal Occult Blood Test (FOBT) (2024-2032) ($MN)
  • Table 4 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Guaiac FOBT (gFOBT) (2024-2032) ($MN)
  • Table 5 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Fecal Immunochemical Test (FIT or iFOBT) (2024-2032) ($MN)
  • Table 6 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Stool DNA Test (sDNA) (2024-2032) ($MN)
  • Table 7 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Multitarget Stool DNA Testing (2024-2032) ($MN)
  • Table 8 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Methylated Gene Testing (2024-2032) ($MN)
  • Table 9 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Panel DNA Tests (2024-2032) ($MN)
  • Table 10 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Biomarker Tests (Blood-based Tests) (2024-2032) ($MN)
  • Table 11 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Tumor M2-PK Stool Test (2024-2032) ($MN)
  • Table 12 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Transferrin Assays (2024-2032) ($MN)
  • Table 13 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Plasma Methylated SEPT9 DNA Assay (2024-2032) ($MN)
  • Table 14 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Liquid Biopsy (2024-2032) ($MN)
  • Table 15 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Other Test Types (2024-2032) ($MN)
  • Table 16 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Imaging Type (2024-2032) ($MN)
  • Table 17 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Colonoscopy (2024-2032) ($MN)
  • Table 18 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Proctoscopy (2024-2032) ($MN)
  • Table 19 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By CT Scan (2024-2032) ($MN)
  • Table 20 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Ultrasound (2024-2032) ($MN)
  • Table 21 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By PET Scan (2024-2032) ($MN)
  • Table 22 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MRI (2024-2032) ($MN)
  • Table 23 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Mode of Offering (2024-2032) ($MN)
  • Table 24 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Physician-Led Screening (2024-2032) ($MN)
  • Table 25 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Direct-to-Consumer (DTC) Home Testing (2024-2032) ($MN)
  • Table 26 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MarCarePlex (2024-2032) ($MN)
  • Table 28 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Cologic (2024-2032) ($MN)
  • Table 29 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Colox (2024-2032) ($MN)
  • Table 30 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By miRDIGN (2024-2032) ($MN)
  • Table 31 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By PanCDx (2024-2032) ($MN)
  • Table 32 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MeSorce CRC (2024-2032) ($MN)
  • Table 33 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 36 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 37 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 38 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.